TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04096885

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine samples, skin and stool swabs
Description: Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
Study: NCT04605588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nitazoxanide
Description: Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
Study: NCT06143605

Intervention type: PROCEDURE
Intervention: salvage treatment
Description: salvage radical surgery or endoscopic resection
Study: NCT04378985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing a Wearable device (Fitbit inspire HR)
Description: 'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'
Study: NCT04052724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group LINGI
Description: Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
Study: NCT01198379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: aspirin 100 mg qd for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01522885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KatGuide versus conventional method (forceps)
Description: According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube insertion
Description: The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
Study: NCT00678496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT Software
Description: Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
Study: NCT02368444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy and Yoga
Description: Group Cognitive Behavioral Therapy Treatment and Yoga Program
Study: NCT02165540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doula
Description: A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
Study: NCT00757523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo Gel
Description: Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duac Gel
Description: Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
Study: NCT01040832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1201081
Description: EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
Study: NCT04336150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive maneuver
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises plus pelvic floor muscle contraction
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive maneuver plus pelvic floor muscle contraction
Description: See information included in arm/group descriptions.
Study: NCT02158221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP
Description: Pituitary adenylate cyclase-activating polypeptide (PACAP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP
Description: Pituitary adenylate cyclase-activating polypeptide (PACAP)
Study: NCT00873444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle™ Acetabular System
Description: A cementless acetabular cup with ceramic liner for use in total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle™ Acetabular System
Description: A cementless acetabular cup with metal liner for use in total hip replacement
Study: NCT05506371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Az+SRP
Description: Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Scaling and root planning (SRP) treatment of periodontitis

Intervention type: DRUG
Group type: OTHER
Intervention: No interventions
Description: Diagnostocs to confirm the healthy state of the gingiva
Study: NCT05314348

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-density surface EMG
Description: High-density surface EMG for fasciculation detection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-density surface EMG
Description: High-density surface EMG for fasciculation detection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound for fasciculation detection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound for fasciculation detection
Study: NCT04111822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate
Description: Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: on crystalloid fluid and Tranexamic acid
Description: Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
Study: NCT03988712

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy, gastroscopy, virtual colonoscopy, CT scan
Description: Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy, gastroscopy, virtual colonoscopy, CT scan
Description: Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy, gastroscopy, virtual colonoscopy, CT scan
Description: Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
Study: NCT00215501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Orally twice a day for 14 days (dosage will vary)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
Study: NCT00413478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
Study: NCT02220127

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GKR with a single shot of the 8 mm collimator
Description: Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GKR with a single shot of the 4 mm collimator
Description: Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
Study: NCT00215501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously weekly for 2 weeks followed by a one week rest period
Study: NCT04605588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ribavirin
Description: Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
Study: NCT02696226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAVR Warfarin
Description: Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAVR Aspirin
Description: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
Study: NCT04605588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hydroxychloroquine
Description: Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
Study: NCT02527265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza
Description: Pharmaceutical form: powder~Route of administration: inhalation
Study: NCT02835521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Joint injection with triamcinolone hexacetonide
Description: joint injection with corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Joint injection with triamcinolone hexacetonide
Description: joint injection with corticosteroids
Study: NCT03824054

Intervention type: PROCEDURE
Intervention: colorectal resection
Description: Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
Study: NCT02913859

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the pelvis
Description: Radiotherapy to the pelvis and prostate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal therapy (LHRH agonist and/or antiandrogens)
Description: life-long hormonal therapy (LHRH agonist and/or antiandrogens)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (LHRH agonist and/or antiandrogens)
Description: life-long hormonal therapy (LHRH agonist and/or antiandrogens)
Study: NCT04667728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Professional continuous glucose monitoring (CGM) sensor (iPro™2)
Description: Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
Study: NCT01506336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 12 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: sunitinib 50 mg/day
Study: NCT02696226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVR Warfarin and clopidogrel
Description: Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVR Aspirin and clopidogrel
Description: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
Study: NCT04845438

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
Description: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
Description: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
Study: NCT01046747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of external fixation pins
Description: The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
Study: NCT01067950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Pancreas Transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Insulin Therapy
Study: NCT04184167

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intermittent fasting 4 months before ICSI
Description: women will start intermittent fasting before starting ICSI by 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fasting 4 months before ICSI
Description: women will start intermittent fasting before starting ICSI by 4 months
Study: NCT02379533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study: NCT02355704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
Study: NCT00339625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat, high fiber, high fruit and vegetable eating plan
Description: Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
Study: NCT01221181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
Study: NCT02218021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study: NCT00215501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously weekly for 2 weeks followed by a one week rest period
Study: NCT02673112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subthreshold exercise (STEP) with mobile health coaching
Description: Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light stretching (LS)
Description: Brief daily stretching routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light stretching (LS)
Description: Brief daily stretching routine.
Study: NCT02061007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole hydrochloride (Hypoxyprobe™-1)
Description: Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional 18F-FMISO PET scan (18F-fluoromisonidazole)
Description: All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Melanoma Metastases
Description: Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
Study: NCT04372589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.
Study: NCT05077189

Intervention type: OTHER
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale
Description: 4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)

Intervention type: OTHER
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale
Description: 4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)
Study: NCT02430792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Football
Description: The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.